US biotech company Genzyme is to invest up to €20 million in its Waterford manufacturing facility to create a research and development capability. The move could create up to 18 new jobs. To date, Genzyme has invested €270 million in its Waterford facilities which now employ 380 people, write s John Collins.

IDA Ireland is providing financial support for the development of the new centre, which will focus on introducing product and process improvements.

Currently, Genzyme Ireland manufactures three products at its Waterford fill and finish facility - Renagel, used in the treatment of kidney disease; Thymoglobulin, an anti-organ rejection agent and Cerezyme, for the treatment of Gaucher disease, a genetic disorder which affects the liver and spleen. The new investment will expand activity, allowing the Waterford operation to incorporate additional product areas such as oncology, cardiovascular, speciality products and renal disease.

"Up to six new product introductions are planned in the next few years, both biologics and oral dose, which will bring to nine the products being supplied from Waterford to our patients globally," said Dominic Carolan, general manager of Genzyme Ireland.

Nasdaq-quoted Genzyme is one of the world's largest biotechnology companies. It was founded in Boston in 1981. It now has annual revenues of over $3 billion (€2.18 billion) and more than 9,500 staff at 70 locations in over 30 countries.

The Massachusetts-based company established its Irish operations in 2001.